Reata Pharmaceuticals Initiates Rolling Submission of New Drug Application with U.S. FDA for Omaveloxolone for the Treatment of Patients with Friedreich ’s Ataxia
If Approved, Omaveloxolone Would Become the First Therapy Indicated for the Treatment of Patients with Friedreich’s Ataxia
PLANO, Texas--(BUSINESS WIRE) January 31, 2022 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA),...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news